Accelerating global AML study: How CSI streamlined Venetoclax and Azacitidine supply across 17 countries in record time

Request: CSI was tasked with sourcing a vast quantity of Venetoclax and Azacitidine for a large pharmaceutical company's global study on Acute Myeloid Leukaemia, covering 17 countries in 3 continents.

 Challenge: The client needed to enroll patients within an extremely short timeframe of 6-months. Additionally, due to the global nature of the study, they also required Certificates of Analysis (CoA), making the feasibility of the request extra challenging.

Solution: Leveraging CSI's strong partnership with AbbVie and generic manufacturers, we were able to cut the study approval time in half and reduce the supply lead time four-fold,  from four months to 4 weeks, including the required documentation. As a result, the client successfully delivered supplies to sites ahead of schedule.